Metabolic Reprogramming and Microenvironment in Pancreatic Adenocarcinoma
Metabolic Reprogramming and Microenvironment in Pancreatic Adenocarcinoma: Identification of New Therapeutic Targets
The present project aims to elucidate the metabolic interactions within the tumor microenvironment of pancreatic adenocarcinoma, both in the primary tumor and in hepatic and pulmonary metastatic sites, as well as in circulating blood biomarkers.
Deciphering these complex interactions aims to identify exploitable vulnerabilities for predicting treatment efficacy or for guiding therapeutic strategies.
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Gedetailleerde beschrijving
Pancreatic adenocarcinoma (PDAC) remains one of the deadliest cancers, with survival rarely exceeding a few months and limited progress despite improved chemotherapy. Its poor prognosis is driven by late diagnosis, therapeutic resistance, and low responsiveness to targeted therapies and immunotherapy.
PDAC is characterized by a dense, immunosuppressive stroma and severe metabolic stress due to poor vascularization. Tumor progression relies heavily on stromal cells-such as cancer-associated fibroblasts and macrophages-as well as metabolic adaptations of cancer cells.
This project focuses on two key PDAC features to identify new biomarkers and therapeutic targets:
- Stromal cell prevalence
- Metabolic reprogramming
Studietype
Inschrijving (Geschat)
Contacten en locaties
Studiecontact
- Naam: Jihane PAKRADOUNI
- Telefoonnummer: +334 91223778
- E-mail: drci.up@ipc-unicancer.fr
Studie Locaties
-
-
-
Marseille, Frankrijk, 13009
- Werving
- Institut Paoli-Calmettes
-
Contact:
- Jihane PAKRADOUNI
- Telefoonnummer: +334 91223778
- E-mail: drci.up@ipc.unicancer.fr
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
- Volwassen
- Oudere volwassene
Accepteert gezonde vrijwilligers
Bemonsteringsmethode
Studie Bevolking
Beschrijving
Inclusion Criteria:
- Age > 18 years
- Signed written informed consent specific to the PROMETAP study
- Affiliation with a social security system
- Treatment and follow-up performed at the Institut Paoli-Calmettes
- Metastatic PDAC requiring biopsy as part of routine care (group1 and 2)
Prior treatment:
- No previous chemotherapy for the "initial" group
- No prior chemotherapy in the metastatic setting for the "Metastatic Relapse" group
- Eligible for chemotherapy (ECOG < 2)
Non-Inclusion Criteria:
- Contraindication to biopsy of the pancreatic tumor or a hepatic or pulmonary metastasis (group 1 and 2)
- Absence of a metastasis accessible to biopsy (group1 and 2)
- Concurrent treatment for another active cancer
- Pregnant or breastfeeding women
- Patients in emergency situations
5. Adult individuals under legal protection (guardianship, trusteeship, judicial protection) or unable to provide informed consent
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
Cohorten en interventies
Groep / Cohort |
Interventie / Behandeling |
|---|---|
|
Groupe 1-Initial
Paired pancreatic and liver/lung metastatic biopsies will be used to establish primary and metastatic cell cultures from tumor specimens obtained during routine diagnostic procedures, along with peripheral blood samples, in a cohort of 12 patients
|
Tumor cells isolation
Isolation of blood monocytes
|
|
Group 2- Relapse
Biopsies of liver or lung metastases obtained at metastatic relapse or progression, along with peripheral blood samples, will be required from 12 patients for the establishment of primary and metastatic cell cultures.
|
Tumor cells isolation
Isolation of blood monocytes
|
|
Group 3- Biological
40 patient samples collected before chemotherapy and paired samples collected during chemotherapy will support molecular and cellular analyses aimed at identifying and assessing novel biomarkers and therapeutic strategies
|
Isolation of blood monocytes
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Evaluation and comparison of biological parameters reflecting metabolic alterations within the tumor microenvironment of pancreatic adenocarcinoma
Tijdsspanne: From sample collection to completion of analyses, estimated at 3 years
|
These analyses aim to identify potential therapeutic targets and to explore diagnostic, prognostic, and predictive biomarkers of treatment response. |
From sample collection to completion of analyses, estimated at 3 years
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Exploratory characterization of metabolic pathways, tumor microenvironment features, and associated biomarkers in pancreatic adenocarcinoma.
Tijdsspanne: From sample collection to completion of analyses, estimated at 3 years
|
|
From sample collection to completion of analyses, estimated at 3 years
|
Medewerkers en onderzoekers
Sponsor
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- PROMETAP-IPC 2022-048
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .